Cancer - Oncology

Cancer / Oncology News From Medical News Today

Ning Wong Of Fox Chase Cancer Center Receives ASCO Cancer Foundation Career Development Award

View Original Article Sat, 17 May 2008 05:00:00 PDT
The American Society of Clinical Oncology Cancer Foundation has selected Yu-Ning Wong, M.D., M.S.C.E., of Fox Chase Cancer Center, as one of 13 clinicians to receive a 2008 Career Development Award. Career Development Awards are presented to physicians in their second, third or fourth year as full-time faculty members in an academic setting. This award marks the third time ASCO has honored Wong's accomplishments since she began her professional career in oncology in 2002.

New Treatment Implications For Ovarian Cancer Unveiled

View Original Article Sat, 17 May 2008 01:00:00 PDT
New research findings from a top clinical investigator at The Cancer Institute of New Jersey (CINJ) indicate the potential for more targeted treatment of ovarian cancer, which is expected to claim more than 15,000 lives nationwide this year, with 480 in New Jersey.

Nexavar Significantly Improves Overall Survival By 47 Percent In Asia Pacific Liver Cancer Study

View Original Article Sat, 17 May 2008 01:00:00 PDT
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that Nexavar(R) (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer versus those receiving placebo. Nexavar also significantly improved time to progression in these patients by 74 percent (HR=0.57; P=0.001).

Significant Anti-Tumor Activity Of NKTR-102 In Patients With Refractory Solid Tumors; Interim Data Published In ASCO 2008 Proceedings

View Original Article Sat, 17 May 2008 00:00:00 PDT
Nektar Therapeutics (Nasdaq: NKTR) announced initial results from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid tumors. The study also demonstrates that Nektar's small molecule PEGylation technology produced an increase in SN38 exposure that was up to six-fold higher than the exposure previously reported with irinotecan at equivalent doses.

Rosetta Genomics To Present Multiple Posters At The 44th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

View Original Article Sat, 17 May 2008 00:00:00 PDT
Rosetta Genomics Ltd. (Nasdaq:ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced that it will present multiple posters at the upcoming ASCO annual meeting in Chicago. The company also has three publication only abstracts available on ASCO's website. The event will take place from May 30 to June 3 at the McCormick Place, Chicago, Illinois. Presented posters: 1.

Disability Resource Directory